TruScreen Group Limited announced that the private medical services provider, Dr. Sulaiman Al-Habib Medical Group (DSAMG), has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC). A cohort of 507 women were examined with TruScreen and LBC across multiple medical centres of DSAMG. The preliminary results confirmed that TruScreen's sensitivity was 83.3% (LBC: 66%) and specificity was 95% (LBC 98%).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 NZD | -.--% | -.--% | -21.74% |
05-30 | Truscreen's Fiscal Year 2024 Loss Widens | MT |
03-13 | Truscreen Group Raises Additional NZ$520,000 via Share Placement; Shares Jump 5% | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.74% | 6.1M | |
+7.49% | 217B | |
+12.15% | 190B | |
+19.29% | 143B | |
+30.45% | 111B | |
+1.67% | 64.59B | |
+15.93% | 52.36B | |
-0.16% | 48.45B | |
-5.10% | 38.03B | |
+0.40% | 35.6B |
- Stock Market
- Equities
- TRU Stock
- News TruScreen Group Limited
- TruScreen Group Limited Announces Clinical Evaluation Results from Saudi Arabia